Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000
Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Dinner Meeting
Meeting Room
Grand Ballroom G-M (Third Floor)
This event will also be webcast live. Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.
Faculty Francois-Clement Bidard, MD, PhD
Medical Oncologist, Institut Curie, Inserm CIC1428
Professor, Versailles/Paris-Saclay University
Vice-Chair, Unicancer Breast Group (UCBG)
Paris, France
Erika Hamilton, MD
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell College of Medicine
New York, New York
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas
Hope S Rugo, MD
Professor of Medicine
Winterhof Family Professor of Breast Cancer
Director
Breast Oncology and Clinical Trials Education
Medical Director
Cancer Infusion Services
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Moderator Neil Love, MD
Research To Practice
Miami, Florida
This symposium is sponsored by Research To Practice and supported by grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, and Stemline Therapeutics Inc. This is not an official program of the San Antonio Breast Cancer Symposium®.
Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Dinner Meeting
MODULE 1: Optimal Integration of CDK4/6 Inhibitors into the Management of ER-Positive Metastatic Breast Cancer (mBC) — Dr Kaklamani
Long-term follow-up from pivotal clinical trials of CDK4/6 inhibitors for premenopausal and postmenopausal patients with ER-positive, HER2-negative mBC
Key findings from the Phase II RIGHT Choice trial comparing ribociclib with endocrine therapy to chemotherapy for patients with aggressive ER-positive mBC
Spectrum, frequency and severity of clinically relevant adverse events reported with CDK4/6 inhibitors
Optimal approaches to prophylaxis, monitoring and management of CDK4/6 inhibitor-associated toxicities
Key data sets attempting to define the optimal timing of therapy with a CDK4/6 inhibitor, the utility of continuing CDK4/6 inhibition beyond disease progression or the benefit of rechallenging with a CDK4/6 inhibitor
MODULE 2: Novel Strategies to Overcome Resistance to Endocrine Therapy — Dr Jhaveri
Published data with alpelisib-based treatment for patients with ER-positive mBC with a PIK3CA mutation
Spectrum, frequency and severity of alpelisib-related toxicities; optimal prevention, monitoring and management strategies
Biological rationale for inhibiting AKT in ER-positive mBC
Mechanism of action of and early clinical trial findings with capivasertib for patients with ER-positive mBC
Key data from the Phase III CAPItello-291 study of capivasertib/fulvestrant for recurrent ER-positive, HER2-negative mBC; FDA priority review designation and potential clinical role of this regimen
Spectrum, frequency, severity and management of toxicities associated with capivasertib
MODULE 3: Current Role of Antibody-Drug Conjugates in the Management of ER-Positive mBC — Dr Rugo
Mechanism of action of trastuzumab deruxtecan (T-DXd); scientific rationale for its activity in HER2-low breast cancer
Key findings among patients with ER-positive disease from the DESTINY-Breast04 trial evaluating T-DXd versus chemotherapy for previously treated HER2-low advanced breast cancer
Incidence, severity and management of interstitial lung disease/pneumonitis and other toxicities with T-DXd
Design, eligibility criteria and key endpoints of the Phase III DESTINY-Breast06 trial assessing T-DXd versus chemotherapy for ER-positive, HER2-low mBC progressing after CDK4/6 inhibitor therapy
Biological rationale for targeting TROP2 in patients with mBC; mechanism of action of sacituzumab govitecan
Design, eligibility criteria and key findings from the Phase III TROPiCS-02 trial evaluating sacituzumab govitecan for ER-positive, HER2-negative mBC
Current role of sacituzumab govitecan in the treatment of ER-positive, HER2-negative mBC
MODULE 4: Current and Future Role of Selective Estrogen Receptor Degraders (SERDs) in the Management of ER-Positive mBC — Prof Bidard
Similarities and differences among the various available and investigational SERDs for breast cancer; implications for efficacy and tolerability
Design, eligibility criteria and results from the Phase III EMERALD trial evaluating elacestrant for patients with ER-positive, HER2-negative mBC with and without ESR1 mutations
FDA approval of elacestrant; implications for biomarker assessment and current clinical management
Early efficacy and safety data with the investigational oral SERDs camizestrant and imlunestrant for ER-positive mBC
Spectrum, frequency, severity and management of toxicities associated with oral SERDs
Ongoing Phase III studies evaluating oral SERDs alone and with other systemic therapies for ER-positive mBC
MODULE 5: Novel Therapies Under Investigation for Patients with ER-Positive mBC — Dr Hamilton
Mechanism of action and structural components of datopotamab deruxtecan (Dato-DXd)
Early clinical trial findings with Dato-DXd for patients with mBC
Recently presented findings from the Phase III TROPION-Breast01 study of Dato-DXd versus investigator’s choice of chemotherapy for pretreated ER-positive, HER2-negative or HER2-low mBC
Incidence of HER3 overexpression across various breast cancer subtypes; mechanism of action and structural components of patritumab deruxtecan (HER3-DXd)
Available findings with HER3-DXd in patients with heavily pretreated mBC
Clinical trial findings with and ongoing investigation of other novel agents and strategies for patients with ER-positive mBC
Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
Learning Objectives
At the conclusion of this activity, participants should be able to
Evaluate biological, patient-specific and treatment-related factors to personalize the selection and sequencing of therapy for newly diagnosed ER-positive, HER2-negative metastatic breast cancer (mBC).
Review available research documenting the correlation between the presence of various biomarkers (eg, PIK3CA mutations, ESR1 mutations, low levels of HER2 expression) and response to specific therapies, and develop optimal testing algorithms for patients with ER-positive mBC.
Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for ER-positive mBC, and appropriately counsel patients regarding the optimal use of these agents.
Recognize the frequency of phosphoinositide-3 kinase pathway mutations in patients with ER-positive mBC, and employ evidence-based approaches designed to target these aberrations.
Understand the mechanism of action of, published research findings with and current and future clinical roles for oral selective estrogen receptor degraders for patients with relapsed/refractory ER-positive mBC.
Appreciate the incidence, characteristics and clinical relevance of ER-positive, HER2-low mBC, and understand available disease-management approaches.
Interrogate published Phase III research findings documenting the efficacy of various novel agents in patients with progressive ER-positive mBC to determine the potential clinical applicability of these approaches.
Assess ongoing clinical research evaluating investigational agents and treatment strategies under development for ER-positive mBC, and counsel patients regarding the potential benefits of trial participation.
CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
Prof Bidard — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Exact Sciences Corporation, GE Healthcare, Gilead Sciences Inc, GSK, Lilly, Menarini Group, Novartis, Pfizer Inc, Rain Oncology, Sanofi; Contracted Research: GE Healthcare, Menarini Silicon Biosystems, Merck KGaA, Novartis, Pfizer Inc, ProLynx Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Rain Oncology, Roche Laboratories Inc, Stemline Therapeutics Inc. Dr Hamilton — Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Medical Pharma Services sro, Mersana Therapeutics Inc, Novartis, Olema Oncology, Orum Therapeutics, Pfizer Inc, Relay Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Theratechnologies, Tubulis, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Accutar Biotechnology Inc, ADC Therapeutics, Akesobio Australia Pty Ltd, Amgen Inc, Aravive Inc, ArQule Inc, Artios, Arvinas, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, BeiGene Ltd, Black Diamond Therapeutics Inc, Bliss Biopharmaceutical, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Context Therapeutics, Cullinan Oncology, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Duality Biologics, eFFECTOR Therapeutics Inc, Ellipses Pharma, Elucida Oncology Inc, EMD Serono Inc, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Inspirna, InventisBio, Jacobio Pharmaceuticals Group Co Ltd, Karyopharm Therapeutics, K-Group Beta, Kind Pharmaceuticals LLC, Leap Therapeutics Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Mersana Therapeutics Inc, Merus BV, Molecular Templates, Novartis, NuCana, Olema Oncology, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, Oncothyreon, ORIC Pharmaceuticals, Orinove Inc, Orum Therapeutics, Pfizer Inc, PharmaMar, Pieris Pharmaceuticals Inc, Pionyr Immunotherapeutics, Plexxikon Inc, Prelude Therapeutics, ProfoundBio, Radius Health Inc, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Repertoire Immune Medicines, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tolmar, Transcenta Holding Limited, Treadwell Therapeutics, Verastem Inc, Zenith Epigenetics, Zymeworks Inc; Nonrelevant Financial Relationship: Dana-Farber Cancer Institute, Verascity Science. Dr Jhaveri — Consultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc; Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. Dr Kaklamani — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Puma Biotechnology Inc, TerSera Therapeutics LLC; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Bristol Myers Squibb; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc, Seagen Inc. Dr Rugo — Consultancy/Advisory Support: Daiichi Sankyo Inc, Napo Pharmaceuticals Inc, Puma Biotechnology Inc, Viatris; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Pionyr Immunotherapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc, Taiho Oncology Inc, Veru Inc; Travel Support to Academic Meetings: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Merck.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, and Stemline Therapeutics Inc.
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom G-M (Third Floor)
Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2023 San Antonio Breast Cancer Symposium is taking place.
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
IN-PERSON Registration
Thank you for your interest in our CME program. At this time onlinepreregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our Onsite Registration Desk will be open at 6:45 PM CT on Tuesday, December 5th. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom G-M (Third Floor) of the Marriott Rivercenter hotel (101 Bowie St) within walking distance of the Henry B Gonzalez Convention Center. We will accommodate as many onsite attendees as possible. Seating will be prioritized for clinicians in practice.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.
NOTICE: Registration for this event is independent of registration for the SABCS Conference.
LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
